Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 25, 2022

SELL
$0.82 - $3.19 $11,434 - $44,484
-13,945 Reduced 17.76%
64,582 $51,000
Q2 2022

Jul 13, 2022

SELL
$2.24 - $6.96 $12,333 - $38,321
-5,506 Reduced 6.55%
78,527 $226,000
Q4 2021

Jan 31, 2022

BUY
$10.0 - $16.78 $210,630 - $353,437
21,063 Added 33.45%
84,033 $936,000
Q3 2021

Oct 26, 2021

BUY
$15.58 - $22.88 $392,148 - $575,889
25,170 Added 66.59%
62,970 $1.03 Million
Q2 2021

Jul 30, 2021

SELL
$11.72 - $26.81 $84,384 - $193,032
-7,200 Reduced 16.0%
37,800 $700,000
Q1 2021

May 03, 2021

BUY
$13.49 - $31.53 $607,050 - $1.42 Million
45,000 New
45,000 $679,000

Others Institutions Holding CDAK

# of Institutions
1
Shares Held
238K
Call Options Held
0
Put Options Held
0

About Codiak BioSciences, Inc.


  • Ticker CDAK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,995,200
  • Market Cap $360K
  • Description
  • Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...
More about CDAK
Track This Portfolio

Track Trellus Management Company, LLC Portfolio

Follow Trellus Management Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trellus Management Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Trellus Management Company, LLC with notifications on news.